Vicor Technologies’ non-invasive diagnostic systems constitute a paradigm shift forward in preventative monitoring for at-risk patients. By leveraging the vastly superior fidelity of data generated by diagnostics systems designed around the point correlation dimension (PD2i®) nonlinear algorithm, developed by VCRT Chief Scientist Dr. James Skinner, the Company is strategically positioned to revolutionize medical diagnostics.

Vicor Therapeutics, the Company’s visionary pharmaceutical segment, develops compounds based on samples isolated from hibernating animals for the treatment and prevention of stroke, heart attacks, kidney failure, obesity and other conditions.

PD2i constitutes a revolutionary new vital sign through the correlation of brain interaction and heart activity that gives doctors a much more accurate picture of the patient’s systems. In cardiac cases, the technology is able to produce sensitivity, accuracy and usability characteristics which are unprecedented.

The Company is busy commercializing this patented PD2i technology in three distinct areas:

• PD2i CA™ – (cardiac analyzer) is able to inexpensively provide superior and accurate profiling for the huge 12M at-risk cardiac patient market

• PD2i Analyzer™ – (granted FDA 510(k) marketing clearance) offers a powerful new framework for analyzing heart rate variability in patients under at-rest or controlled exercise conditions

• PD2i VS™ – (vital signs) a trauma triage diagnostics system which is in ongoing collaborative trials with the U.S. Army Institute of Surgical Research

Let us hear your thoughts: Vicor Technologies, Inc. Message Board